Mainz Biomed N.V. (MYNZ)
- Previous Close
0.8568 - Open
0.8500 - Bid 0.5950 x 200
- Ask 1.1000 x 200
- Day's Range
0.8250 - 0.8794 - 52 Week Range
0.8100 - 6.0000 - Volume
33,578 - Avg. Volume
97,874 - Market Cap (intraday)
18.056M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6200 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.
mainzbiomed.com65
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYNZ
Performance Overview: MYNZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYNZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYNZ
Valuation Measures
Market Cap
18.75M
Enterprise Value
19.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.54
Price/Book (mrq)
5.77
Enterprise Value/Revenue
21.33
Enterprise Value/EBITDA
-0.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-93.42%
Return on Equity (ttm)
-303.20%
Revenue (ttm)
895.48k
Net Income Avi to Common (ttm)
-26.3M
Diluted EPS (ttm)
-1.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
7.07M
Total Debt/Equity (mrq)
228.39%
Levered Free Cash Flow (ttm)
-13.61M